American Dental Partners is one of the nation's leading business partners to dental group practices. The Company is affiliated with 26 dental groups that have 241 dental facilities with approximately 2,123 operatories located in 18 states.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: With the exception of the historical information contained in this news release, the matters described herein contain "forward-looking" statements that involve risk and uncertainties that may individually or collectively affect the matters herein described, including but not limited to the Company's risks associated with overall or regional economic conditions, dependence upon affiliated dental practices, contracts its affiliated practices have with third-party payors, government regulation of the dental industry, impact of health care reform, dependence upon service agreements and the impact of any terminations or potential terminations of such contracts, business interruptions, the outcome of pending litigation and the Company's acquisition and affiliation strategy, which are detailed from time to time in the "Risk Factors" section of the Company's filings with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December 31, 2008 and quarterly reports on Form 10-Q.

Contacts:
Gregory A. Serrao
Chairman,
President and Chief Executive Officer
781-224-0880

Breht T. Feigh
Executive Vice President,
Chief Financial Officer and Treasurer
781-224-0880

SOURCE: American Dental Partners, Inc.

In addition, ADPI has also signed a 40-year service agreement with Christie Dental Practice Group. The closing of the acquisition is expected to occur on or about December 1, 2009, at which time the service agreement will become effective.

Cobblestone | Harris Williams is acting as financial advisor to Christie Dental.

Deal Type    Acquisition
Sub-Category Asset Purchase
Deal Status  Announced: 2009-11-16

Deal Participants

Target 1 (Company) Christie Dental Partners, Inc. -  Non-clinical Assets
Target 2 (Company) Christie Dental Practice Group, P.L. - Non-Clinical Assets
Acquirer (Company) American Dental Partners, Inc.
Vendor 1 (Company) Christie Dental Practice Group, P.L.
Vendor 2 (Company) Christie Dental Partners, Inc.

"We are excited that Christie Dental has chosen to affiliate with American Dental Partners. Christie Dental has a proven track record of strong growth in attractive markets," said Gregory A. Serrao, Chief Executive Officer of American Dental Partners. "Together, we intend to build upon Christie Dental's well-recognized brand and reputation for high quality care."

"An affiliation with American Dental Partners represents an excellent opportunity for Christie Dental. Our business values and cultures are well-aligned," said Dr. Todd E. Christie, founder and Chief Executive Officer of Christie Dental Partners and an owner of Christie Dental Practice Group. "Based on our knowledge of American Dental Partners' demonstrated commitment to its affiliated practices, we are excited about the future growth potential for our dental practice that this affiliation brings."

Cobblestone | Harris Williams (www.cobblestonehw.com), a specialty group of Harris Williams & Co., acted as the exclusive advisor to Christie Dental.

American Dental Partners is one of the nation's leading business partners to dental group practices. The Company is affiliated with 26 dental group practices that have 241 dental facilities with approximately 2,123 operatories located in 18 states.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: With the exception of the historical information contained in this news release, the matters described herein contain "forward-looking" statements that involve risk and uncertainties that may individually or collectively affect the matters herein described, including but not limited to the Company's risks associated with overall or regional economic conditions, dependence upon affiliated dental practices, contracts its affiliated practices have with third-party payors, government regulation of the dental industry, impact of health care reform, dependence upon service agreements and the impact of any terminations or potential terminations of such contracts, business interruptions, the outcome of pending litigation and the Company's acquisition and affiliation strategy, which are detailed from time to time in the "Risk Factors" section of the Company's filings with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December 31, 2008 and quarterly reports on Form 10-Q.

Contacts:
Gregory A. Serrao
Chairman, President and
Chief Executive Officer
781-224-0880

Breht T. Feigh
Executive Vice President, Chief
Financial Officer and Treasurer
781-224-0880

American Dental Partners, Inc.
401 Edgewater Place, Suite 430
Wakefield, MA  01880
Phone: 781/224-0880
Fax: 781/224-4216

SOURCE: American Dental Partners, Inc.

In a press release out on November 16, American Dental Partners Announces Affiliation With Christie Dental

WAKEFIELD, MA, Nov 16, 2009 -- American Dental Partners, Inc. (NASDAQ: ADPI) announced today that it has entered into an agreement to acquire certain non-clinical assets of Christie Dental Practice Group, P.L. and Christie Dental Partners, Inc. (collectively, "Christie Dental") and enter into a 40-year service agreement with Christie Dental Practice Group, P.L. The closing of the acquisition is expected to occur on or about December 1, 2009, at which time the service agreement will become effective. Christie Dental will be American Dental Partners' first affiliation with a dental group practice in the state of Florida.

American Dental Partners is one of the nation's leading business partners to dental group practices. The Company is affiliated with 26 dental group practices that have 241 dental facilities with approximately 2,123 operatories located in 18 states.

Fiserv, Inc. (NASDAQ: FISV) trading at $48.14 per share on trading volume of 39,159 shares.

In a press release out on November 16, Fiserv Ranks First in North America, Fifth Overall, in Chartis' RiskTech100 Report on Global Risk Technology Providers

Momentum in solutions for enterprise financial risk management help drive Fiserv higher in 2009 ranking

BROOKFIELD, Wis., Nov 16, 2009 -- Fiserv, Inc. (NASDAQ: FISV), the leading global provider of financial services technology solutions, announced today that Chartis Research's RiskTech100(TM), a comprehensive annual study of the top global technology firms active in risk management, has ranked Fiserv fifth overall and number one in North America among firms in the RiskTech100 geographic sectors category.

About Fiserv

Fiserv, Inc. (NASDAQ: FISV) is the leading global provider of information management and electronic commerce systems for the financial services industry, driving innovation that transforms experiences for financial institutions and their customers. Ranked No. 1 on the FinTech 100 survey of top technology partners to the financial services industry, Fiserv celebrates its 25th year in 2009. For more information, visit www.fiserv.com.

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) trading at $28.32 on a volume of 66,309 shares

In a press release out on November 16, Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc.

EMERYVILLE, Calif., Nov 16, 2009 -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Neogen Corporation (Nasdaq: NEOG) trading at $32.34 on a volume of 5,604 shares

In a press release out on November 16, Neogen Announces 3 for-2 Stock Split

LANSING, Mich., Nov 16, 2009 -- Neogen Corporation (Nasdaq: NEOG) today announced that its Board of Directors has approved a 3-for-2 stock split. With the split, shareholders of record on Nov. 30, 2009, will receive one additional share of stock for each two shares held.

Neogen Corporation develops and markets products dedicated to food and animal safety. The Company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.